Article Text

Download PDFPDF

#413 Integrated genomic and transcriptomic analysis reveal the activation of PI3K signaling pathway in non-HPV-associated cervical cancer
  1. Yi Wang,
  2. Huijuan Yang and
  3. Wei Jiang
  1. Fudan University Shanghai Cancer Center, Shanghai, China


Introduction/Background Cervical cancers are one of the most threatening female reproductive system tumors worldwide. Of whom, Non-HPV-associated cervical cancers (NHPV-CCs) are rare and poorly understood, yet associated with poorer outcomes compared to HPV-associated cervical cancers. To shed light on the molecular tumorigenesis of NHPV-CCs, we performed an integrated genomic and transcriptomic analysis to identify the characteristics of NHPV-CCs.

Methodology Twenty-five out of 1010 cervical cancer patients were identified to be HPV-negative by PCR, RT-PCR, and RNA-seq in our cancer center in 5 years. Genomic alterations and transcriptomic differences were profiled by whole exome sequencing (WES) and RNA-seq in all 25 patients. The TCGA-CESC cohort was analyzed for validation. The efficacy of PI3Kα inhibitor BYL719 in NHPV-CCs was detected in cell lines and patient-derived xenografts (PDX).

Results NHPV-CCs were characterized by poor prognosis and high tumor mutation burden compared to HPV-associated cervical cancers, as PIK3CA listing the top genomic alteration(36%). The PI3K/AKT signaling and FGFR signaling were significantly enriched in NHPV-CCs in both cohorts. The PI3Kα specific inhibitor BYL719 demonstrated superior tumor inhibitory efficacy in both the NHPV-CC cell line and PDX models. Furthermore, based on gene expression profiles, we identified two subtypes of NHPV-CCs: the metabolism subtype characterized by fatty acid metabolism, and the immune-suppression subtype characterized by upregulation of PD-1 and NOTCH signaling.

Conclusion We clarified the prevalence of NHPV-CCs and compared the clinicopathology and molecular features of NHPV-CCs. Our findings highlight the significance of PIK3CA mutation and PI3K/AKT pathway in NHPV-CC tumorigenesis, suggesting the clinical potential of PI3Ka inhibitor in NHPV-CCs patients.

Abstract #413 Figure 1

PI3K signaling pathway was highly activated in non-HPV-associated cervical cancers (CCs). A Somatic mutations in HPV-negative CCs. The upper panel shows the number of mutational events for each sample, the middle panel shows the clinical features and the bottom panel shows the transition/transversions type. B Sanger sequencing of PIK3CA mutation in both HPV-positive and HPV-negative CCs. C Heatmap of significantly differential expression in cervical cancers. D Bar plot shows cancer-related pathways enriched by GSEA between HPV-negative and HPV-positive CCs in SHCC cohort. E GSEA plot displays that PI3K/AKT signaling was enriched in HPV-negative CCs in both cohorts while TP53 signaling pathway was enriched in HPV-positive CCs. FGFR pathways were also enriched in HPV-negative CCs. F Relative levels of transcripts of main effectors in the PI3K/AKT signaling pathway. * P<0.05; ** P<0.01; ***P<0.001. Wilcox test.

Disclosures There are no financial conflicts of interest to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.